InvestSMART

4DMedical Limited (ASX:4DX)

ALERT: Price-sensitive ASX Announcement for 4DX
Current share price for 4DX : $3.680 1.855 (101.64%)+
Announcement
Release
30 Oct 2025 10:12AM
Price at Release
$1.825
Full Release
download
Summary
4DMedical Limited has achieved significant milestones in Q1 FY26, including FDA clearance for their CT:VQ™ technology, making it a groundbreaking non-contrast, CT-based ventilation-perfusion imaging solution. The company has secured immediate reimbursement from CMS, accelerating its commercial rollout in the U.S. Stanford University was the first to adopt the technology commercially. 4DMedical expanded its Lung Health Screening Program in Brazil, added new hospital partners, and secured a pilot agreement with Royal Melbourne Hospital in Australia. Financially, the company reported $1.4 million in operating revenue with a strong cash position of $33.5 million. They experienced a substantial increase in scan production and are on track for further commercialization and growth initiatives.
Key Points
  • FDA clearance of CT:VQ™ technology.
  • Immediate CMS reimbursement secured.
  • Stanford University adopted CT:VQ™ commercially.
  • Expansion of Lung Health Screening Program in Brazil.
  • Pilot agreement with Royal Melbourne Hospital in Australia.
  • Operating revenue of $1.4 million in Q1 FY26.
  • Cash balance of $33.5 million at quarter end.
  • Production of over 74,345 scans, up 105.6% YoY.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.